By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Hematopoietic stem cell mobilizer > Mozobil
Hematopoietic stem cell mobilizer

Mozobil

https://themeditary.com/drug/mozobil-2368.html
Medically Reviewed by Philip Thornton, DipPharm TheMediTary.Com | Reviewed: Jul 13, 2023  Additional Content by TheMediTary.Com

Generic name: plerixafor [ pler-ix-a-fore ]

Drug class: Hematopoietic stem cell mobilizer, Other immunostimulants

Dosage form: subcutaneous injection

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Plerixafor

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Mozobil?

Mozobil works by helping your bone marrow release stem cells into your bloodstream so they can be collected and transplanted back into the body.

Mozobilis used in people with non-Hodgkin's lymphoma or multiple myeloma.

Mozobil may also be used for purposes not listed in this medication guide.

Warnings

Do not receive Mozobil without telling your doctor if you are pregnant. It could harm the unborn baby. Use effective birth control, and tell your doctor if you become pregnant during treatment. You should not receive Mozobil if you are allergic to plerixafor, or if you have leukemia.

Before you receive this medicine, tell your doctor if you have kidney disease.

Mozobil is given as an injection in a hospital or clinic setting.

Before receiving Mozobil, you will be given another medication that will help your bone marrow produce stem cells and certain white blood cells that help support your immune system.

To be sure Mozobil is not causing harmful effects, your blood will need to be tested often

Before taking this medicine

You should not be treated with Mozobil if you are allergic to plerixafor, or if you have leukemia.

If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before you take Mozobil, tell your doctor if you have kidney disease.

Plerixafor may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using Mozobil and for at least 1 week after your last dose. Tell your doctor if you become pregnant.

You may need to have a negative pregnancy test before starting this treatment.

You should not breastfeed while receiving this medication.

Mozobil pregnancy and breastfeeding warnings (more detail)

How should I take Mozobil

Mozobil is injected under the skin. A healthcare provider will give you this injection.

You will be watched closely for at least 30 minutes to make sure you do not have an allergic reaction.

Before receiving Mozobil, you will be given a medication called a granulocyte (GRAN-yoo-loe-site) colony stimulating factor (G-CSF). A G-CSF helps your body produce stem cells and white blood cells to help support your immune system.

Mozobil works together with the G-CSF by causing stem cells and granulocytes produced in the bone marrow to circulate into your bloodstream where they can be collected in blood drawn from your vein.

After your blood is drawn, it will be processed so that the needed stem cells and granulocytes can be separated from other unneeded parts of the blood. These stem cells and granulocytes will then be "transplanted" back into your body.

Your blood will need to be tested often during your treatment.

Dosing information

Usual Adult Dose for non-Hodgkin's Lymphoma:

Dosing Based on Actual Patient Body Weight:
-83 kg or Less:
20 mg fixed dose or 0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis

-Greater than 83 kg and Less than 160 kg:
0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis

Duration of Therapy: Up to 4 consecutive days

Maximum Dose: 40 mg/day

Comments:
-The drug volume to be administered should be calculated using the following equation: 0.012 x actual patient body weight (kg) = administration dose (mL)
-The dosing has been calculated based on actual patient body weight up to 175% of ideal body weight; dosing and treatment of patients weighing more than 175% of ideal body weight have not been investigated.
-Granulocyte-colony stimulating factor (G-CSF) 10 mcg/kg should be administered once daily in the morning for 4 consecutive days prior to the first dose of this drug and on each morning prior to apheresis.

Use: Indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Usual Adult Dose for Multiple Myeloma:

Dosing Based on Actual Patient Body Weight:
-83 kg or Less:
20 mg fixed dose or 0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis

-Greater than 83 kg and Less than 160 kg:
0.24 mg/kg subcutaneously once in the evening, approximately 11 hours prior to initiation of each apheresis

Duration of Therapy: Up to 4 consecutive days

Maximum Dose: 40 mg/day

Comments:
-The drug volume to be administered should be calculated using the following equation: 0.012 x actual patient body weight (kg) = administration dose (mL)
-The dosing has been calculated based on actual patient body weight up to 175% of ideal body weight; dosing and treatment of patients weighing more than 175% of ideal body weight have not been investigated.
-Granulocyte-colony stimulating factor (G-CSF) 10 mcg/kg should be administered once daily in the morning for 4 consecutive days prior to the first dose of this drug and on each morning prior to apheresis.

Use: Indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Detailed Mozobil dosage information
Mozobil Dosage information (more detail)

Before Taking

You should not be treated with Mozobil if you are allergic to plerixafor, or if you have leukemia.

If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before you take Mozobil, tell your doctor if you have kidney disease.

Plerixafor may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using Mozobil and for at least 1 week after your last dose. Tell your doctor if you become pregnant.

You may need to have a negative pregnancy test before starting this treatment.

You should not breastfeed while receiving this medication.

Mozobil pregnancy and breastfeeding warnings (more detail)

Related/similar drugs

Darzalex, Blenrep, Tecvayli, Carvykti, methotrexate, rituximab, cyclophosphamide

What happens if I miss a dose?

Because you will receive Mozobil in a clinical setting, you are not likely to miss a dose.

What happens if I overdose?

Since this medication is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.

Overdose symptoms may include stomach discomfort, severe dizziness, or fainting.

What should I avoid while using Mozobil?

Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are receiving Mozobil.

Mozobil side effects

Get emergency medical help if you have signs of an allergic reaction to Mozobil: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Tell your caregivers at once if you have a serious side effect such as:

  • easy bruising or bleeding, unusual weakness;

  • feeling like you might pass out; or

  • severe pain in your left upper stomach, spreading to your shoulder blade.

Common Mozobil side effects may include:

  • irritation where the medication was injected;

  • nausea, vomiting, diarrhea;

  • headache, dizziness;

  • tiredness; or

  • joint pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

See more: Mozobil Side Effects

More about Mozobil (Plerixafor [ pler-ix-a-fore ])

Dosage information
Mozobil Side Effects
During pregnancy
Mozobil Prescribing Information
Drug images
Side effects
Drug class: Hematopoietic stem cell mobilizer

Related treatment guides

Non-Hodgkin's Lymphoma
Multiple Myeloma
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by